ArticleFunctional & integrative genomics2025
Immune-based molecular subtyping of triple-negative breast cancer via SNF-CC and functional validation of key immune-associated genes.
Article in Functional & integrative genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its aggressive nature and lack of targeted treatment options. Emerging evidence highlights the critical role of immune infiltration patterns in TNBC progression and prognosis, yet a comprehensive classification system integrating immune and transcriptomic features remains elusive. In this study, we employed the xCell algorithm to characterize immune infiltration across TNBC samples and utilized the Similarity Network Fusion and Consensus Clustering (SNF-CC) method to identify molecular subtypes. Our analysis revealed three distinct TNBC subtypes with marked heterogeneity in transcriptomic profiles and immune microenvironment composition. Subtype 1 exhibited high immune infiltration, while Subtype 3 demonstrated immunosuppressive characteristics. Functional enrichment analysis linked subtype-specific differentially expressed genes (DEGs) to pathways such as T-cell activation and cytokine signaling. Protein-protein interaction networks identified key hub genes (PTPRC, CD4, and UBE2C) showing elevated expression in TNBC tissues. Experimental validation in breast cancer cell lines confirmed that knockout of PTPRC, CD4, or UBE2C significantly impaired proliferation, migration, and invasion, while rescue experiments restored these oncogenic phenotypes. These findings establish an immune-based molecular subtyping framework for TNBC and uncover pivotal genes driving tumor progression. Our work provides novel insights into TNBC heterogeneity and identifies potential therapeutic targets for precision immunotherapy, advancing strategies to improve clinical outcomes in this recalcitrant malignancy.
Indexed as
Identifiers
40627035What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.